|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Ono Pharma |
| Information provided by: | Ono Pharma |
| ClinicalTrials.gov Identifier: | NCT00046761 |
Purpose
The primary objective of this study is to compare the efficacy of ONO-2506 versus placebo in neurological stroke outcome in patients with acute ischemic stroke.
| Condition | Intervention | Phase |
|
Cerebrovascular Accident |
Drug: ONO-2506 |
Phase II Phase III |
| Drug Information available for: | Arundic acid |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | A Study to Evaluate the Effects of ONO-2506 Intravenous Infusion in Patients With Acute Ischemic Stroke |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Patient must not have all three of the following findings:
Contacts and Locations![]() |
Show 148 Study Locations |
| Ono Pharma |
| Study Director: | Bryan Due, Ph.D. | Ono Pharma |
More Information
| Study ID Numbers: | 2506/INT0104 |
| First Received: | October 2, 2002 |
| Last Updated: | May 5, 2006 |
| ClinicalTrials.gov Identifier: | NCT00046761 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|